作者
Anani Badje, Raoul Moh, Delphine Gabillard, Calixte Guéhi, Mathieu Kabran, Jean-Baptiste Ntakpé, Jérôme Le Carrou, Gérard M Kouame, Eric Ouattara, Eugène Messou, Amani Anzian, Albert Minga, Joachim Gnokoro, Patrice Gouesse, Arlette Emieme, Cyprien Rabe, Baba Sidibé, Gustave Nzunetu, Lambert Dohoun, Abo Yao, Synali Kamagate, Solange Amon, Amadou-Barenson Kouame, Aboli Koua, Emmanuel Kouamé, Marcelle Daligou, Denise Hawerlander, Simplice Ackoundzé, Serge Koule, Jonas Séri, Alex Ani, Fassery Dembélé, Fatoumata Koné, Mykayila Oyebi, Nathalie Mbakop, Oyewole Makaila, Carolle Babatunde, Nathaniel Babatunde, Gisèle Bleoué, Mireille Tchoutedjem, Alain-Claude Kouadio, Ghislaine Sena, Sahinou-Yediga Yededji, Sophie Karcher, Christine Rouzioux, Abo Kouame, Rodrigue Assi, Alima Bakayoko, Serge K Domoua, Nina Deschamps, Kakou Aka, Thérèse N'Dri-Yoman, Roger Salamon, Valérie Journot, Hughes Ahibo, Timothée Ouassa, Hervé Menan, André Inwoley, Christine Danel, Serge P Eholié, Xavier Anglaret, Gérard-Menan Kouame, Yao Abo, Serge-K Domoua, Hervé Ménan, Ben-Ahoussi Ndja, Blandine Adou, Constance Kanga, Eba Aoussi, Emmanuel Bissagnene, Olivier Ba-Gomis, Yves-Alain Zike, Claude Akakpo, Madeleine Sassan-Morokro, Max Mobio, Bamba Doféré, Koman Mesmin, Alain Attia, Alassane Mahassadi, Apollinaire Horo, Armel Oussou, Marie-Laure Chaix, Gilles Peytavin, Mariatou Koné, Kouamé N'Guessan, Raïmi Fassassi, Serge Niangoran, Annabel Desgrées-du-Loû, France Lert, Rosemary Dray Spira, Kevin Jean, Romuald Konan, Franck Bohoussou, Cyril Yao-Yapi, Larissa N'guessan-Koffi, Bertine Siloué, Adoulaye Cissé, Adrienne Aboua, Sylvie Konan, Antoine Kouamé, Celestin N'Chot, Elvis Amani, Gwenaëlle Clouet, Bruno Debono, Geneviève Chêne, Mireille Dosso, Pierre-Marie Girard, Vincent Jarlier, Jean-Marie Masumbuko, Christian Perronne, Papa-Salif Sow, Serge-Paul Eholié
发表日期
2017/11/1
期刊
The Lancet global health
卷号
5
期号
11
页码范围
e1080-e1089
出版商
Elsevier
简介
Background
Temprano ANRS 12136 was a factorial 2 × 2 trial that assessed the benefits of early antiretroviral therapy (ART; ie, in patients who had not reached the CD4 cell count threshold used to recommend starting ART, as per the WHO guidelines that were the standard during the study period) and 6-month isoniazid preventive therapy (IPT) in HIV-infected adults in Côte d'Ivoire. Early ART and IPT were shown to independently reduce the risk of severe morbidity at 30 months. Here, we present the efficacy of IPT in reducing mortality from the long-term follow-up of Temprano.
Methods
For Temprano, participants were randomly assigned to four groups (deferred ART, deferred ART plus IPT, early ART, or early ART plus IPT). Participants who completed the trial follow-up were invited to participate in a post-trial phase. The primary post-trial phase endpoint was death, as analysed by the intention-to-treat principle …
学术搜索中的文章
A Badje, R Moh, D Gabillard, C Guéhi, M Kabran… - The Lancet global health, 2017